Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
Zanwar S, Gertz MA, Muchtar E, Buadi FK, Kourelis T, Gonsalves W, Go RS, Hayman S, Kapoor P, Binder M, Cook J, Dingli D, Leung N, Lin Y, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S, Dispenzieri A. Zanwar S, et al. Among authors: hwa yl. Leukemia. 2024 Jun;38(6):1423-1426. doi: 10.1038/s41375-024-02243-5. Epub 2024 Apr 9. Leukemia. 2024. PMID: 38594348 Free PMC article. No abstract available.
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment.
Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Hwa YL, Gonsalves W, Kyle RA, Dispenzieri A. Kourelis TV, et al. Among authors: hwa yl. Leukemia. 2016 May;30(5):1079-85. doi: 10.1038/leu.2015.344. Epub 2015 Dec 16. Leukemia. 2016. PMID: 26669974
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK. Sidana S, et al. Among authors: hwa yl. Leukemia. 2018 Mar;32(3):729-735. doi: 10.1038/leu.2017.286. Epub 2017 Sep 18. Leukemia. 2018. PMID: 28919633
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Hobbs M, Fonder A, Kyle RA, Rajkumar SV, Kumar SK, Gonsalves WI. Sidana S, et al. Among authors: hwa yl. Leukemia. 2018 Jun;32(6):1421-1426. doi: 10.1038/s41375-018-0063-7. Epub 2018 Feb 21. Leukemia. 2018. PMID: 29483709 Free PMC article.
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance.
Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Lakshman A, et al. Among authors: hwa yl. Leukemia. 2018 Aug;32(8):1811-1815. doi: 10.1038/s41375-018-0030-3. Epub 2018 Jan 30. Leukemia. 2018. PMID: 29568092 No abstract available.
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.
Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Muchtar E, et al. Among authors: hwa yl. Leukemia. 2018 Oct;32(10):2240-2249. doi: 10.1038/s41375-018-0060-x. Epub 2018 Feb 20. Leukemia. 2018. PMID: 29581546
Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.
Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Muchtar E, et al. Among authors: hwa yl. Leukemia. 2019 Feb;33(2):527-531. doi: 10.1038/s41375-018-0258-y. Epub 2018 Sep 26. Leukemia. 2019. PMID: 30258095 No abstract available.
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK. Sidana S, et al. Among authors: hwa yl. Leukemia. 2019 Mar;33(3):730-738. doi: 10.1038/s41375-018-0271-1. Epub 2018 Oct 15. Leukemia. 2019. PMID: 30323358
Comparative analysis of staging systems in AL amyloidosis.
Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Muchtar E, et al. Among authors: hwa yl. Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z. Epub 2019 Jan 23. Leukemia. 2019. PMID: 30675009 No abstract available.
121 results